4-叠氮基异喹啉 | 20377-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4-叠氮基异喹啉
• 英文名称: 4-azidoisoquinoline
• 英文别名: 4-isoquinolyl azide
• CAS: 20377-03-1
• 化学式: C₉H₆N₄
• 分子量: 170.173
• InChiKey: WGTJICQXDAAKIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  13.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.65
• 氢给体数：
  0.0
• 氢受体数：
  2.0

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  4-叠氮基异喹啉 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以73%的产率得到4-azidoisoquinoline N-oxide
  参考文献：
  名称：

  Studies on diazepines. XXI. Photochemical synthesis of 1H-2,4-benzodiazepines from 4-azidoisoquinolines.

  摘要：

  在甲醇钠存在下辐照 4-叠氮异喹啉（1a-e）会导致环扩张，生成 5-甲氧基-1H-2, 4-苯并二氮杂卓（10）：产品的结构通过以下化学研究和光谱分析得到证实。用盐酸或甲醇中的酸性氧化铝处理二氮杂卓（10）会导致缩环，得到 1-氨基异吲哚烯类（14），用乙酸酐处理会得到开环产物（16）。通过进一步辐照，二氮杂环庚烷（10）还可转化为 1-甲氧基异吲哚烯类（19），而通过氧化间甲苯胺或四乙酸铅处理，则可转化为二氮杂环庚烷-3-酮（21）。

  DOI：

  10.1248/cpb.33.4564
• 作为产物：
  描述：

  4-溴异喹啉 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 sodium carbonate 、 sodium ascorbate 、 L-脯氨酸 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-叠氮基异喹啉
  参考文献：
  名称：

  Biological evaluation of new mimetics of annonaceous acetogenins: Alteration of right scaffold by click linkage with aromatic functionalities

  摘要：

  A small library of analogues of annonaceous acetogenins through click linkage with aromatic moieties is established using a convergent modular fragment-assembly approach. These analogues exhibited low micromolar inhibitory activities against the proliferation of several human cancer cell lines. Structure-activity relationship (SAR) of these analogues indicates that replacement of the methoxy groups of ubiquinone ring with methyl groups is proved to be a useful strategy for improving the anticancer activity of quinone-acetogenin hybrids. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.062

文献信息

• Copper(II)-Catalyzed Conversion of Aryl/Heteroaryl Boronic Acids, Boronates, and Trifluoroborates into the Corresponding Azides: Substrate Scope and Limitations
  作者：Courtney Aldrich、Kimberly Grimes、Amol Gupte

  DOI：10.1055/s-0029-1218683

  日期：2010.5

  incorporating B-C(sp³) bonds are unreactive under the reaction conditions. The copper(II)-catalyzed boronic acid-azide coupling reaction is further extended to both boronate esters and potassium organotrifluoroborate salts. The method described herein complements existing procedures for the preparation of aryl azides from the respective amino, triazene, and halide derivatives and we expect that it will greatly

  我们报告了铜 (II) 催化的有机硼化合物转化为相应的叠氮化物衍生物。评估了一系列系统的苯基硼酸衍生物，以检查取代基的空间和电子效应对反应产率以及官能团兼容性的重要性。杂环底物也被证明参与了这种温和的反应，而结合了 BC( sp³) 键在反应条件下不反应。铜 (II) 催化的硼酸-叠氮化物偶联反应进一步扩展到硼酸酯和有机三氟硼酸钾盐。本文描述的方法补充了从各自的氨基、三氮烯和卤化物衍生物制备芳基叠氮化物的现有程序，我们预计它将极大地促进铜和钌催化的叠氮化物-炔环加成反应，以制备多种功能化的 1-芳基-或1-杂芳基-1,2,3-三唑衍生物。 叠氮化物 - 有机硼化合物 - 铜催化 - 1,2,3-三唑
• Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides
  作者：Mikhail O. Konev、T. Andrew McTeague、Jeffrey W. Johannes

  DOI：10.1021/acscatal.8b02954

  日期：2018.10.5

  dual catalytic nickel/ruthenium system from aryl azides and aryl electrophiles. Photoreduction of the aryl azide is proposed to proceed through an arylnickel-azide complex, which upon reduction and loss of nitrogen, generates a nickel(III) species capable of facile reductive elimination to afford the desired C–N bond formation. A variety of functionalized (hetero)aryl electrophiles are shown to participate

  通过光氧化还原介导的双催化镍/钌体系，由芳基叠氮化物和芳基亲电试剂制备药用相关的二芳基胺。提议通过芳基镍-叠氮化物配合物进行芳基叠氮化物的光还原，该复合物在氮的还原和损失后会生成能够容易地消除以提供所需的C–N键形成的镍（III）物种。各种官能化的（杂）芳基亲电试剂显示参与偶联，包括碘化物，溴化物，氯化物和三氟甲磺酸酯。该反应易于建立并且在环境条件下进行，不排除氧气或湿气。
• [EN] POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS<br/>[FR] COMPOSÉS POLYHÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE METTL3
  申请人：STORM THERAPEUTICS LTD

  公开号：WO2021111124A1

  公开（公告）日：2021-06-10

  The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

  本发明涉及具有以下式（I）的化合物，其作为METTL3（N6-腺苷-甲基转移酶70kDa亚基）酶活性的抑制剂：X-Y-Z（I），其中X、Y和Z如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增生性疾病（如癌症）、自身免疫疾病以及METTL3活性相关的其他疾病或病况中的用途。
• Syntheses of heterocyclic compounds, part XXI. Oxazoles from pyrolysis of aryl and heterocyclic azides in a mixture of acetic and polyphosphoric acid
  作者：E. B. Mullock、H. Suschitzky

  DOI：10.1039/j39680001937

  日期：——

  Pyrolysis of 2-azido-naphthalene, -anthraquinone, and various azido-heterocycles in a mixture of polyphosphoric and acetic acid results in fusion of an oxazolo-moiety on to the parent system. The scope of this convenient oxazole synthesis in its widest sense is discussed.

  在多磷酸和乙酸的混合物中2-叠氮基萘，蒽醌和各种叠氮基杂环的热解导致恶唑基部分融合到母体系统上。从最广泛的意义上讨论了这种方便的恶唑合成的范围。
• Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections
  作者：Philine Kirsch、Saskia C. Stein、Aylin Berwanger、Julia Rinkes、Valentin Jakob、Thomas F. Schulz、Martin Empting

  DOI：10.1016/j.ejmech.2020.112525

  日期：2020.9

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.